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Abstract
Background: Glioblastoma multiforme (GBM) is the most malignant central nervous system tumor. Alkylating
agent, temozolomide (TMZ), is currently the first-line chemotherapeutic agent for GBM. However, the sensitivity
of GBM cells to TMZ is affected by many factors. And, several clinic trials, including co-administration of TMZ with
other drugs, have failed in successful treatment of GBM. We have previously reported that Netrin-4 (NTN4), a
laminin-like axon guidance protein, plays a protective role in GBM cell senescence upon TMZ-triggered DNA
damage. However, the master regulator of NTN4 needs further elucidation. Epidermal growth factor/Epidermal
growth factor receptor (EGF/EGFR) can modulate the expression of various extracellular matrix related molecules,
and prevent DNA damage in GBM cells. In this study, we investigated the relationship between EGF/EGFR signaling
and NTN4, and explored their effect on therapeutic efficacy in GBM cells upon TMZ treatment.
Methods: Co-expression analysis were performed by using the RNA sequencing data from NIH 934 cell lines and
from single cell RNA sequencing data of GBM tumor. The co-expressing genes were used for GO enrichment and
signaling pathway enrichment. mRNA expression of the target genes were quantified by qPCR, and cell senescence
were investigated by Senescence-Associated Beta-Galactosidase Staining. Protein phosphorylation were observed
and analyzed by immunoblotting. The RNA sequencing data and clinical information of TMZ treated patients were
extracted from TCGA-glioblastoma project, and then used for Kaplan-Meier survival analysis.
Results: Analysis of RNA sequencing data revealed a potential co-expression relationship between NTN4 and EGFR.
GO enrichment of EGFR-correlated genes indicated that EGFR regulates GBM cells in a manner similar to that in
central nervous system development and neural cell differentiation. Pathway analysis suggested that EGFR and
its related genes contribute to cell adhesion, extracellular matrix (ECM) organization and caspase related signaling.
We also show that EGF stimulates NTN4 expression in GBM cells and cooperates with NTN4 to attenuate GBM cell
senescence induced by DNA damage, possibly via AKT and ERK. Clinical analysis showed that co-expression of EGFR
and NTN4 significantly predicts poor survival in TMZ-treated GBM patients.
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Conclusions: This study indicates that EGF/EGFR regulates and cooperates with NTN4 in DNA damage resistance in
GBM. Therefore, our findings provide a potential therapeutic target for GBM.
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Background
Glioblastoma multiforme (GBM) is the most common
malignant tumor of the central nervous system [1, 2].
Even with treatment, the median survival time of glio-
blastoma patients following diagnosis is 12 ~ 15months
[3, 4]. Alkylating agent, temozolomide (TMZ), is currently
the first-line chemotherapeutic agent for the treatment of
glioblastoma. The therapeutic action of TMZ is exerted by
triggering DNA damage, which induces GBM cell apop-
tosis and senescence [5]. However, even with adjuvant
TMZ chemotherapy, the 2-year overall survival rate of
GBM patients only reaches ~ 27% [6–8]. The therapeutic
efficacy of TMZ depends on self-repair of DNA damage
[6], the rescue effect from RTK signaling [9–11], and cell
remodeling in the microenvironment [12].
Our previous study showed that Netrin-4 (NTN4)
protects glioblastoma cells from TMZ-induced senes-
cence through rescuing the phosphorylation of AKT
and ERK [13]. NTN4 was originally identified as a se-
creted laminin-like axon guidance protein in neuronal
development [14, 15]. In addition to the central nervous
system, NTN4 is broadly expressed in non-neural cells,
and regulates tissue development and tumor progression
by modulating various cellular functions [16–23]. In glio-
blastoma, NTN4 is highly expressed at the tumor invading
edge [24] and promotes glioblastoma cell proliferation via
ITGB4-Akt signaling [25]. Although the expression of
netrin-associated receptors including ITGA6 and ITGB4,
is regulated by various growth factors, especially by Epi-
dermal growth factor/Epidermal growth factor receptor
EGF/EGFR [26–29], the upstream regulators of NTN4 ex-
pression and of GBM cell senescence remain largely
unknown.
EGF is a growth factor that stimulates cell growth,
proliferation, and differentiation [30]. EGF binds to
EGFR family receptors with high affinity. This stimu-
lates ligand-induced dimerization, activating the intrin-
sic protein-tyrosine kinase activity of the receptor. The
tyrosine kinase activity, in turn, initiates signal trans-
duction cascades that results in a variety of biochemical
changes within the cell: a rise in intracellular calcium
levels, increased glycolysis and protein synthesis, and
increases in the expression of certain genes including
the gene for EGFR, that lead to the regulation of various
biological functions [31, 32]. EGF/EGFR signaling can
protect cells from DNA damage through different down-
stream signaling pathways [33–35]. However, clinical trials
of EGF/EGFR inhibitors failed to show any therapeutic
efficacy, even in combination with TMZ [36, 37]. There-
fore, upon induction of DNA damage in GBM cells,
co-inhibition of RTK signaling and the extracellular
matrix remodeling, may provide a new strategy for GBM
treatment. Here, using experimental and bioinformatic
analyses, we describe EGF/EGFR upregulation of NTN4
expression and EGF/EGFR cooperation with NTN4 to at-
tenuate GBM cell senescence induced by DNA damage.
Methods
Immunoblot analysis, immunofluorescence, transfection of
cells, total RNA extraction, reverse transcription, and
real-time reverse transcription-PCR were performed as de-
scribed [13, 25]. Senescence-associated beta-galactosidase
staining and bioinformatic analysis were performed as
below.
Cell lines and reagents
U251MG cells (Health Science Research Resources Bank,
Osaka, Japan) were cultured according to the supplier’s in-
structions. Primary GBM cells were isolated according to
previous description [38, 39], and then cultured in in
Dulbecco’s modified essential culture medium (DMEM)
supplied with 10% heat inactivated fetal calf serum (FCS)
(Gibco, USA), 100 IU/ml penicillin, 50mg/ml streptomycin
and 1% L-glutamine.. In this study, all experiments have ob-
tained patients’ consent and been approved by the Ethic
Committee for Harbin Medical University. The following
primary antibodies and recombinant protein were used:
anti-NTN4 from R&D systems; anti-phospho-p44/43MAPK
(ERK1/2, Thr202/Tyr204), anti-phospho-mammalian target
of rapamycin (mTOR; Ser2448), anti-phospho-SRC(Ser416),
and anti-phospho-AKT (Ser473) from Cell Signaling Tech.
(Danvers, MA, USA); anti-β-tubulin from Santa Cruz Bio-
technology (Santa Cruz, CA; recombinant NTN4 from
R&D Systems (Minneapolis, MN, USA).
H2O2 and EGF treatment
H2O2 (Merck KGaA, Germany) treatment was performed
on > 90% confluent cells (~ 1 × 105 cells per well in 6-well
plates) to avoid variability of H2O2 toxicity as described in
[40]. Cells were incubated in 2ml/well culture medium
containing 150 μM H2O2 for 48 h at 37 °C in a 5% CO2 at-
mosphere, and then split to 5000 cells per well in 24-well
plates in fresh DMEM.
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EGF (Sigma E9644) treatment was performed at a con-
centration of 50 ng/ml, and was added to growing cells
in 0.05% serum DMEM in 24-well plates every 2 days.
Subsequently, the cells were gently washed twice with
PBS, and then cultured under 10% serum fresh DMEM
for further experiments.
Transfection of cells
Cells were cultured in six-well plates to 50 to 80% conflu-
ence and transfected using 2 μg plasmid DNA and 6 μl
FuGENE 6 transfection reagent for each transfection ac-
cording to the manufacturer’s instructions (Boehringer
Mannheim, Mannheim, Germany). Stably transfected cells
were selected with ∼0.8mg/ml G418 (Gibco/Invitrogen) in
complete medium. The expression levels of each indicated
gene in transfected cells were analyzed by Q-RT-PCR.
Senescence-associated Beta-galactosidase staining (SA
β-gal staining)
Cells were cultured in 24-well plates at densities of
3000~ 5000 cells per well for the indicated times. Subse-
quently, the cells were washed once with PBS and then
fixed in PBS containing 0.5% glutaraldehyde at room
temperature for 20 min. After two PBS washes, the cells
were incubated with SA β-gal substrate solution (1 mg/
ml X-gal, 40 mM citric acid-sodium phosphate buffer,
pH 6.0, containing 5 mM potassium ferricyanide, 5 mM
potassium ferrocyanide, 150 mM NaCl, and 2mM
MgCl2) at 37 °C in the dark for 16–20 h [40]. The reac-
tion was terminated by removing SA β-gal substrate
solution and washing twice with PBS. The cells were
stored in 70% glycerol at 4 °C. The cells were photo-
graphed using an Axiovert 200 inverted epifluorescence
microscope (Carl Zeiss). The ratio of blue-stained cells
was analyzed with ImageJ (National Institutes of Health,
Bethesda, MD).
Bioinformatic analysis
Co-expression analysis was performed using Spearman’s
rank correlation coefficient between the expression of
EGFR and all other genes, in the dimension of all single
cells. Distance Correlation analysis of gene expression
was described previously [41–43]. Briefly, for each gene,
pairwise Euclidean distances were generated in the di-
mension of all cells. After scaling the values by mean,
the co-variance of EGFR and other genes was calculated
upon the distance matrix between EGFR and all other
genes. GO enrichment was assessed using Python Pack-
age jdrudolph/goenrich with modification on the enrich-
ment of GO bioprocess, and the pathway enrichment
was analyzed by Python Package PyPathway. Lifelines
Package was used for Kaplan-Meier survival analysis. 3D
axes plots and Violin plots were generated by Matplotlib
and Seaborn.
Statistical analysis
All numerical values represent the mean ± SE or SD.
Statistical significance was determined with the nonpara-
metric Mann-Whitney U test.
Results
EGF stimulates Netrin-4 expression in U251MG cells
ITGA6, ITGB4 are regulated by different growth factors
[20, 27, 44–47]. Therefore, as a potential ligand of laminin
integrins, NTN4, is possibly expressed in response to
stimulation by growth factors. By analyzing RNA sequen-
cing data of NIH 934 human cell lines [48], we explored
the co-expression relationships among NTN4, ITGA6,
ITGB4, EGFR, and ErBB2 in these cell lines. We found
that expression of NTN4 significantly correlated with
EGFR (Fig. 1a). Meanwhile, we confirmed that the ex-
pression of EGFR is tightly linked to that of ITGA6 and
ITGB4. These findings are in line with our previous ob-
servation that NTN4/ITGB4 protect GBM cells from
TMZ-induced cell senescence, and indicate that NTN4
expression is possibly monitored by the EGF signaling
pathway. To further understand the downstream path-
way and biological functions of EGF signaling in glio-
blastoma, we extracted single-cell RNA sequencing
(scRNAseq) data of grade IV glioblastoma [49]. After
overlapping the results from Spearman correlation
coefficient and Distance (pDist) Correlation analyses,
we obtained a list of 191 genes that significantly correl-
ate with EGFR, including NTN4 (SI Table I). Using
these 191 genes, we further enriched for GO bioprocess
and signaling pathways underlying EGFR signaling (SI
Table II). Cell adhesions, ECM organization and
Caspase-related signaling pathways were the top effec-
tors of EGFR expression (Fig. 1b). Nervous system
development and glial cell differentiation were the top
GO bio-processes of EGFR-related genes (Fig. 1c). To
validate this observation, U251MG GBM cells and two
primary GBM cell lines, GBM-14042 and GBM-112D
cells, were treated with EGF for 24 h, 48 h, and 96 h.
U251MG express the mRNA of both EGFR and NTN4
at decent level, but does not express MGMT [13, 50],
and the similar expression profile were detected in
both GBM-14042 and GBM-112D cells by qRT-PCR
(Fig. 1d). In addition, both of GBM-14042 and
GBM-112D cells do not express MGMT (negative
data, not shown here). Furthermore, we observed that
NTN4 expression were significantly increased upon
EGF stimulation at both mRNA level (Fig. 1e) and
protein level (Fig. 1f ).
The GO function and signaling pathway enrichment re-
vealed that EGFR might contribute to cell differentiation,
central nervous system development, ECM re-organization,
and netrin/DCC related caspase activation. Meanwhile,
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EGF stimulation upregulates the expression of NTN4.
Thus, using a senescence assay induced by H2O2 and
TMZ, we observed the relationship between EGF stimula-
tion/NTN4 expression and GBM cell senescence.
NTN4 and EGF protect GBM cells from DNA damage-
induced senescence
We have previously demonstrated that NTN4 contributes
to the resistance of TMZ-triggered GBM cell senescence
[13]. Hydrogen peroxide can also induce cell senescence by
triggering DNA single- and double-strand breaks. Here we
used a H2O2-induced senescence assay to further under-
stand the effect of NTN4 and EGF on GBM cell senes-
cence. We constructed U251MG cells expressing NTN4
(Fig. 2a). We then detected the number of senescent cells
after H2O2 treatment using a senescence-associated
beta-galactosidase assay. We observed significantly fewer
senescent NTN4-overexpressing cells compared with mock
control cells (Fig. 2b). Thus, NTN4 overexpression delayed
U251MG cell senescence induced by H2O2. We then
detected whether EGF could reduce the number of
senescent U251MG cells induced by H2O2. On the 4th
day after H2O2 treatment, we observed less senescence
in U251MG cells treated with EGF compared with
non-EGF treated cells. On the 7th day after H2O2 treat-
ment, the number of senescent cells in the EGF treat-
ment group was significantly less than that in the
non-treatment control group. (Fig. 2c). There was a
significant difference in U251MG senescence between
cells treated and not treated with EGF for 7 days. With
EGF (40 ng/ml) treatment, senescence of U251MG
cells induced by H2O2 decreased. The concentration
of 40 ng/ml EGF inhibited U251MG cell senescence
efficiently.
To reconfirm the effect of NTN4 and EGF on GBM
cell senescence induced by DNA damage, we treated
U251MG cells, GBM-14042 and GBM-112D cells with
TMZ to induce cell senescence. TMZ-treated cells were
co-administrated NTN4, EGF, or combined NTN4/EGF,
and then senescent cells were quantified. Both EGF and
NTN4 treatment delayed cell senescence compared with
non-treatment control cells, while the combined NTN4/
EGF treatment did not provide any additive effect on
rescuing cell senescence (Fig. 2d-f ). Therefore, either
EGF or NTN4 can attenuate GBM cell senescence trig-
gered by DNA damage, and they may recruit similar
pathways in response to DNA damage.
Fig. 1 EGF contributes to NTN4 expression in GBM cells. a On the basis of RNA sequencing data from 934 NIH cell lines, we calculated the
Spearman product-moment correlation coefficient. The co-expression analysis revealed that the expression of EGFR correlates with NTN4
(R_value = 0.573) and ITGB4 (R_value = 0.539). b & c According to scRNA sequencing data of glioblastoma, 191 genes co-expressed with EGFR
were enriched by overlapping Spearman product-moment correlation coefficient and distant correlation analysis. These 191 genes were further
used for signaling pathway enrichment and GO bioprocess enrichment. ECM organization and Caspase-related signaling pathways were enriched
by signaling pathway analysis (b). Nervous system development and glial cell differentiation were enriched by GO bioprocess analysis (c). d Using
Q-RT-PCR, the mRNA levels of NTN4 and EGFR were determined in two primary glioblastoma cell lines: GBM-14042 and GBM-112D. e-f EGF
treatment was performed at the concentration of 20 ng/ml and was re-applied every 48 h. 24 h, 48 h, and 96 h after EGF treatment, the mRNA
levels of NTN4 were determined in U251MG, GBM-14042 and GBM-112D cells by Q-RT-PCR (e). After treatment for 48 h and 96 h, the expression
of NTN4 was 2 to 3-fold higher than control group. The enhancing effects of EGF on NTN4 expression (green) were also detected by
immunofluorescence in U251MG at 48 h and 72 h, and the Dapi staining was shown in blue (f)
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The EGF/NTN4 signaling axis contributes to the
phosphorylation of Src, ERK and AKT
We then explored the combined effect of EGF and
NTN4 on four major downstream signaling pathways
in U251MG cells: ERK, AKT, Src and mTOR (Fig. 3).
EGF treatment for 48 h slightly but not significantly in-
creased p-ERK, p-AKT levels, and strongly upregulated
Src phosphorylation. Short term EGF stimulation with
or without NTN4 treatment for 48 h can enhance
p-ERK, p-AKT, p-Src, and p-mTOR levels. Treatment
with NTN4 for 48 h did not significantly alter any sig-
naling pathways. Short term treatment of wild type
U251MG cells with NTN4 increased p-ERK, p-AKT,
and p-Src levels, while this effect was covered by long
term stimulation with EGF. Interestingly, short-term
NTN4 treatment had a continuously stimulatory effect
on p-mTOR, even after 48 h EGF treatment. Thus, the
EGF/NTN4 axis may contribute to the phosphorylation
of ERK, AKT, and Src. Meanwhile, NTN4 itself may
have a separate effect on mTOR phosphorylation.
Co-expression of EGFR/NTN4 predicts poor survival in
TMZ-treated GBM patients
We have shown that EGF and NTN4 contribute to re-
sistance of cell senescence induced by DNA damage.
The co-expression relationship of EGFR/NTN4
prompted us to further explore the effect of EGFR/
NTN4 co-expression in GBM patients. We extracted
RNA sequencing data and clinical information for 92
TMZ-treated GBM patients from The Cancer Genome
Atlas Research Network (TCGA)-glioblastoma dataset
[51]. To visualize the relationship among EGFR, NTN4,
and patient survival, we constructed a 3D axes plot, with
EGFR expression, NTN4 expression, and patient survival
on the X, Y, and Z, axes, respectively. In this plot, al-
though EGFR and NTN4 expression did not significantly
Fig. 2 EGF and NTN4 delayed cell senescence induced by H2O2 and TMZ. (a) The expression levels of NTN4 were determined by Q-RT-PCR in
U251MG cells overexpressing NTN4 (NTN4.pcDNA3) and in mock control U251MG cells (Mock). (b) Five days after H2O2 treatment, mock cells and
NTN4.pcDNA3 cells were fixed and analyzed by beta-gal staining. H2O2 triggered senescence of U251MG cells, while NTN4 overexpression
significantly decreased the number of senescent cells induced by H2O2. (c) After the H2O2 treatment, U251MG cells were treated with EGF (40 ng/
mL) every two days. On the 4th and 7th day after EGF treatment, U251MG cells were fixed and analyzed by the beta-gal staining. Four days after
EGF treatment, the number of senescent U251MG cells was significantly less compared with control cells. Seven days after EGF treatment, the
number of senescent U251MG cells was ~ 2-fold less than in EGF non-treated groups. (d-f) After TMZ treatment, U251MG cells were treated with
EGF (40 ng/mL), NTN4 (50 ng/ml), and EGF + NTN4, separately. All the proteins were re-supplied every two days. After treatment for 4 days, TMZ
strongly induced senescence in U251MG cells (d), GBM-14042 (e) and GBM-112D cells (f), while EGF, NTN4, and EGF + NTN4 attenuated the pro-
senescence effect of TMZ. Mean ± SE, n ≥ 3, * p-value < 0.05, ** p-value < 0.01
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correlate with poor patient survival (Fig. 4a & b, up-left),
co-expression of EGFR and NTN4 did correlate with
poor patient survival (Fig. 4c, up-left). To validate the
significance of this trend, we selected the 20% of patients
with either the highest or lowest expression of target
genes and assessed the difference in patient survival be-
tween the two groups (Fig. 4a, b, c, right-left). Kaplan-
Meier analysis showed that neither EGFR nor NTN4
expression significantly correlated with patient survival
after TMZ treatment, while co-expression of EGFR/
NTN4 predicts poor patient survival (Fig. 4a, b, c, lower
panels). To exclude a random effect of EGFR/NTN4 ex-
pression, we analyzed NTN1 and co-expression of
EGFR/NTN1 as a control, and observed no correlation
with patient survival. Lastly, we generated a violin plot
to summarize the comparison of patient survival among
all the groups mentioned above, and only the high
co-expression of EGFR/NTN4 group showed a con-
densed low survival time (Fig. 4e).
Discussion
In this study, we report a cooperative resistance mechan-
ism in GBM cells involving NTN4 and EGFR following
DNA-damage induction. We observed the EGF/EGFR sig-
naling pathway as an upstream regulator of NTN4. Acti-
vating mutations or amplification of EGFR are observed in
45–57.4% of glioblastomas [52, 53], and frequently occur
in the “Classical” subgroup of glioblastomas [51, 54, 55].
Cells with EGFR gene amplification preferentially move to
the infiltrating edges of glioblastoma, indicating that
EGFR signaling confers a special advantage for GBM pro-
gression and migration [56]. Laminin-related integrins,
Fig. 3 EGF regulates NTN4 to stimulate the phosphorylation of AKT, ERK, and Src. U251MG cells were treated with EGF (40 ng/mL) and NTN4 (50
ng/ml) for 48 h. Then these cells were treated with NTN4 (50 ng/mL) or EGF (40 ng/mL) for 10 min or 30 min. Subsequently, cells were lysed and
the phosphorylation of AKT, ERK, Src and mTOR detected. a Short term stimulation of EGF significantly enhanced AKT phosphorylation, and a
similar phenomenon was observed after 48 h of stimulation with recombinant NTN4. Addition of exogenous NTN4 increased p-AKT levels at 10
min and 30min. After EGF stimulation for 48 h, NTN4 was not able to further increase p-AKT. Long term addition of exogenous NTN4 did not
affect p-ERK. However, short term stimulation of EGF significantly enhanced ERK phosphorylation, regardless of long term NTN4 stimulation.
Addition of exogenous NTN4 increased levels of p-ERK at 30 min. p-ERK did not show any significant change after 48 h of stimulation with EGF.
b Long term addition of exogenous NTN4 did not affect p-Src. Stimulation with EGF for 10 min significantly increased p-Src, with or without 48 h
of stimulation with exogenous NTN4. Stimulation with EGF for 30 min enhanced p-Src, which was abolished after treatment with NTN4 for 48 h.
Addition of exogenous NTN4 increased p-ERK after 10 min. Although p-Src was strongly up-regulated after 48 h of treatment with EGF, NTN4 did
not additionally stimulate Src phosphorylation. Long term addition of exogenous NTN4 did not affect p-mTOR. EGF significantly increased
p-mTOR levels at both 10min and 30 min, with or without 48 h stimulation with exogenous NTN4. Addition of exogenous NTN4 significantly
enhanced p-mTOR at 30 min. EGF treatment for 48 h did not change p-mTOR levels; however, p-mTOR levels were strongly increased when
combined with NTN4 stimulation for 30 min. Mean ± SE, n ≥ 3, * p-value < 0.05, ** p-value < 0.01
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ITGA6 and ITGB4, are co-expressed with different
growth factors, especially ones involved with EGF/EGFR
signaling [27–29, 47]. Interestingly, a potential integrin-as-
sociated protein, netrin-4, is also highly expressed at the
invading edge of glioma. By bioinformatic analysis and the
EGF stimulation experiment, we confirmed that EGF/
EGFR contribute to NTN4 expression.
Using single cell RNA sequencing data from glioblast-
oma, we enriched for genes co-expressed with EGFR, and
further explored the GO bioprocesses and related path-
ways of EGFR. We found that the gene sets co-expressed
with EGFR are involved in various biological functions
and pathways, including cell differentiation in GBM, ECM
organization, the caspase related pathway, and Notch sig-
naling. These findings are consistent with previous studies
[57–60].
Via this analysis and the experiment above, we found
that EGF/EGFR regulates NTN4 expression; and that
EGFR possibly modulates caspase activation via netrin/
netrin receptors [61, 62]. Thus, EGF/EGFR signaling may
regulate netrin-related pathways to protect cells from
DNA damage. H2O2 or TMZ can trigger DNA damage in
GBM cells. Using these two models, we provide in vitro
evidence that either EGF or NTN4 is sufficient to attenu-
ate GBM cell senescence induced by DNA-damage. Inter-
estingly, in vitro co-administration of EGF and NTN4 did
Fig. 4 The co-expression of EGFR and NTN4 contribute to TMZ resistance in GBM patients. Clinical information and gene expression data of
totally 92 TMZ-treated GBM patients were extracted from the TCGA-glioblastoma dataset. To describe the contribution of EGFR and NTN4 to
survival time of TMZ-treated patients, we used both 3D axes surface plots and Kaplan-Meier analysis. In 3D axes surface plots, the X and Y axes
represent the expression of EGFR and NTN4, respectively. The Z axis represents survival time of each patient. Here, we selected the 20% of
patients (top 19 patients) with either the highest (right side of red line) or lowest (left side of green line) expression of target genes and
compared the survival time. a High EGFR expression slightly but not significantly predicts poor patient survival. b The expression of NTN4
itself does not correlate with patient survival. c Weighted high expression of EGFR and NTN4 significantly predicts poor patient survival. d NTN1
was used as a control in this study. Neither single NTN1 expression nor weighted expression of EGFR and NTN1 correlated with patient survival.
e Violin plot representing the relationship between all different combinations of EGFR/NTN4/NTN1 expression and survival time of TMZ-treated
GBM patients. Dark grey bar-box indicates a significant p-value (< 0.05). Only when both EGFR and NTN4 were highly expressed in patients, were
survival times lowest in TMZ-treated patients
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not show an additive effect on resistance to DNA damage.
These results indicate that EGF/EGFR attenuate GBM cell
senescence induced by DNA damage, at least partially via
the expression of NTN4.
ERK and AKT pathways are essential in mediating the
protective role of EGF/EGFR against DNA damage [33–
35]. Our results show that EGF is able to provide add-
itional stimulation to ERK and AKT upon NTN4 treat-
ment, suggesting that EGF may regulate the stimulatory
effect of NTN4 on ERK and AKT. However, NTN4 can
modulate mTOR phosphorylation independent of EGF,
indicating alternative biological functions in response to
NTN4.
As an oncogene, EGFR has long been proposed as a
drug target for cancer treatment. Many agents were
developed as small molecule tyrosine kinase inhibitors
(TKIs) to interfere with EGFR tyrosine kinase activity
and its downstream signaling. Although EGFR inhibi-
tors were efficacious on GBM cells in vitro, clinical
trials performed to date have been disappointing at
targeting EGFR in glioblastoma. Despite the availability
of TKIs for a broad spectrum of diseases, none of
them demonstrate efficacy for glioblastoma treatment,
either as a single agent [37] or in combination with
other reagents [63, 64] or radiation [65, 66]. In Phase
I/II trials, EGFR inhibitors co-administered with TMZ
failed to show any effects [36, 37]. Consistent with the
clinical trials, our bioinformatic analysis of TCGA glio-
blastoma revealed that neither EGFR nor NTN4 pre-
dicts significant survival in TMZ-treated patients. This
suggests that targeting either EGFR or NTN4 singly can-
not improve survival of TMZ-GBM patients. However,
Patients with high expression of both EGFR and NTN4
show significantly shortened survival time. This result is
not in agreement with the observation that no additive ef-
fect of EGFR and NTN4 on resistance was seen in vitro;
however, this could be because to two reasons. First, in
addition to classical ERK/AKT resistant pathways regu-
lated by EGF/EGFR, NTN4 may also modulate ECM/
integrin in vivo [67], which can induce ECM
reorganization and mechano-transductions. Thus, after
EGF/EGFR stimulation, NTN4-ECM-integrins may
contribute to the resistance of DNA damage in GBM
patients. Second, netrin molecules can regulate micro-
glia, T cells, endothelial cells and leukocytes [68–72].
All these cells may be located near GBM cells in vivo.
A potential intercellular resistance mechanism, initiated
by EGF/EGFR and exerted by both EGF and NTN4,
may contribute to TMZ-DNA damage resistance in
GBM patients.
In summary, combinatorial approaches for targeting
the EGFR/NTN4 axis and inducing DNA damage, for
example, by temozolomide, may be beneficial in GBM
therapy.
Conclusions
We find that EGF/EGFR regulates and cooperates with
NTN4 in DNA damage resistance in GBM. Therefore,
this provides a potential therapeutic target to the EGFR/
NTN4 axis for GBM therapy.
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